Aardema, M.J. & MacGregor, J.T. (2002). Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat. Res. 29;499, 13-25.
Bayat, A. (2002). Science, medicine, and the future Bioinformatics. BMJ. 324, 1018-1022. Available here.
Bushati, N. & Cohen, S.M. (2007). microRNA functions. Annu. Rev. Cell Dev. Biol. 23, 175-205.
Crews, K.R. (2006). Individualizing chemotherapeutic treatment of colorectal cancer. Am. J. Health Syst. Pharm. 63, Suppl. 2, S12-S17.
Cummins, J.E. (2007). What's on your plate? Drug Discov. Dev. 10, G2-G3.
Dove, A. (2007). RNAi Moves Down the Pipeline. Drug Discov. Dev. Available here.
Echeverri, C.J. & Perrimon, N. (2006). High-throughput RNAi screening in cultured cells: A user's guide. Nat. Rev. Genet. 7, 373-384.
Friedman, A. & Perrimon, N. (2006). High-throughput approaches to dissecting MAPK signaling pathways. Methods. 40, 262-271.
Hahn, K.K., Wolff, J.J. & Kolesar, J.M. (2006). Pharmacogenetics and irinotecan therapy. Am. J. Health Syst. Pharm. 63, 2211-2217.
Human Genome Project (HGP). (2003). Genome glossary. US Department of Energy (DOE). Available here.
MAQC Consortium. (2006). The microarray quality control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nature Biotechnology. 24, 1151-1161. Available here.
McGee, P. (2006). Genomics: The next step in the sequence. Available here.
Moggs, J.G., Goodman, J.I., Trosko, J.E. & Roberts R.A. (2004). Epigenetics and cancer: implications for drug discovery and safety assessment. Toxicol. Appl. Pharmacol. 196, 422-430.
Reinberg, S. (2007). Drug Industry Seeks Tests to Spot Side Effect Risks. Available here.
Watson, R.E. & Goodman, J.I. (2002). Epigenetics and DNA methylation come of age in toxicology. Toxicol. Sci. 67, 11-16.
|
